Crackdown On Bad Regenerative Medicine Could Benefit Gene Therapy

US FDA to offer series of guidances on regenerative product development – and declares gene therapies eligible for RMAT – as enforcement against 'unscrupulous actors' continues.

Bad Apple
Will the bad apples make the public distrust the good ones?

US FDA is vowing a crackdown on "unscrupulous actors" in the regenerative medicine industry as part of a policy that could also benefit honest manufacturers.

Coming on the heels of a series of recent enforcement actions against stem cell centers in Florida and California, agency...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cell & Gene Therapies

More from Advanced Technologies